Telix Pharmaceuticals Limited (TLX) reported a stronger first half, with revenue and adjusted EBITDA rising sharply year over year while the company advanced multiple cancer programs, expanded its manufacturing network, and strengthened its balance sheet. TLX stock climbed 2.48% to $12.42, recovering from a mid-morning low near $12.10.

Revenue Rises 22% as Margins Improve

Telix posted first-half group revenue of $477 million, a 22% increase from the previous year and a result that tracked near the upper end of the company's full-year revenue guidance. Telix currently expects annual revenue between $950 million and $970 million.

Group gross margin rose two percentage points to 55% during the reporting period, while Precision Medicine gross margin reached 65%, up one percentage point from a year earlier. Higher product volumes, product mix changes, and operating efficiencies supported the improvement.

Adjusted EBITDA jumped 146% year over year to $52 million in the first half, a figure that included a $40 million non-refundable payment linked to Telix's Regeneron collaboration. The company continued to invest heavily, directing $124 million toward research and development programs, underscoring the balance Telix is managing between near-term commercial growth and longer-cycle pipeline development.

Precision Medicine Drives Commercial Growth

The Precision Medicine business increased revenue 27% from the same period last year, as Illuccix and Gozellix generated higher sales volumes while expanding their positions in prostate cancer imaging. Segment adjusted EBITDA rose 26% to $132 million.

Telix also advanced several regulatory programs across major international markets. The company completed enrollment for an Illuccix Phase 3 study in Japan, and Chinese regulators accepted its Illuccix application and began their formal review process. Telix moved its brain and kidney cancer imaging products through additional regulatory milestones: the FDA assigned Pixclara a September 11, 2026 decision target date, and the company continues preparing its Zircaix application for resubmission after addressing outstanding FDA requirements. Those steps matter because they extend the company's commercial footprint beyond its current core markets while keeping the regulatory path tied to formal review timelines.

Therapeutics Pipeline Advances

Of total research spending, Telix invested $68 million in its therapeutics pipeline during the first half. Its ProstACT Global program met initial safety and dosimetry goals for its lead prostate cancer therapy, and the FDA cleared the program to advance into the next trial stage.

The OPTIMAL-PSMA Phase 2 study completed enrollment of 120 patients with advanced prostate cancer, and Telix dosed initial patients in studies involving prostate, kidney, and brain cancer therapies. These programs form part of the company's strategy to develop revenue beyond diagnostic imaging products, while the current milestones show the pipeline still progressing through early and mid-stage clinical work.

Manufacturing Expands Despite Segment Loss

Telix Manufacturing Solutions generated $146 million in total segment revenue during the period, comprising $89 million from external sales and services and $58 million in internal revenue. The segment recorded a $23 million adjusted EBITDA loss following higher infrastructure and logistics investment.

Production capacity expanded across Australia, Belgium, Japan, and the United States. Telix's Seneffe facility completed its first GMP production run involving a lutetium-based therapeutic candidate.

The company ended June with $252 million in cash after generating $23 million in positive operating cash flow, giving it additional flexibility as it continues investing in manufacturing scale-up and clinical development alongside its commercial business.